The effect of curcumin supplementation on pain caused by neuropathy in patients treated with taxanes

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20220802055602N1

Enrollment

Registered

2022-08-20

Start date

2022-08-11

Completion date

Unknown

Last updated

2022-08-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Neuropathy caused by receiving taxanes. Condition 2: cancer.

Interventions

Intervention group: patients with chemotherapy-induced neuropathy who receive 500 mg curcumin tablets once a day for up to 3 months..

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Having symptoms of neuropathy Confirmation of neuropathy by ncv test and doctor's examination

Exclusion criteria

Exclusion criteria: Cancer patients who have neuropathy caused by factors other than chemotherapy drugs, such as diabetics, pregnant and lactating mothers, people who receive painkillers such as morphine

Design outcomes

Primary

Measure	Time frame
??? ???????? (?? ???? ???? ??? ????????) ???????? ?? ????? ???? ?????? ???? ?????? ?? ?????? ??????. Timepoint: Evaluation of neuropathy in patients is before the administration of drugs, in the middle of the administration period (45 days after the administration of the interventions i.e. the administration of the first dose of drugs, placebo and positive control) and after the treatment (up to 1 month after the last administration of the interventions). Method of measurement: Nerve conduction speed test, doctor's examination and questionnaire.	—

Measure

Time frame

??? ???????? (?? ???? ???? ??? ????????) ???????? ?? ????? ???? ?????? ???? ?????? ?? ?????? ??????. Timepoint: Evaluation of neuropathy in patients is before the administration of drugs, in the middle of the administration period (45 days after the administration of the interventions i.e. the administration of the first dose of drugs, placebo and positive control) and after the treatment (up to 1 month after the last administration of the interventions). Method of measurement: Nerve conduction speed test, doctor's examination and questionnaire.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFatemeh Rezaie

Kerman University of Medical Sciences

Fatemeh.dsdt4@gmail.com+98 34 3132 5690

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026